PDLI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PDL BioPharma Inc's quarterly additional paid-in capital increased from Mar. 2016 ($-117.2 Mil) to Jun. 2016 ($-116.5 Mil) but then declined from Jun. 2016 ($-116.5 Mil) to Sep. 2016 ($-119.5 Mil).
PDL BioPharma Inc's annual additional paid-in capital increased from Dec. 2012 ($-234.1 Mil) to Dec. 2013 ($-233.2 Mil) and increased from Dec. 2013 ($-233.2 Mil) to Dec. 2014 ($-119.9 Mil).
Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.
Additional Paid-In Capital is calculated as
|Additional Paid-In Capital||=||(Issue Price||-||Par Value)||*||Shares Outstanding|
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
PDL BioPharma Inc Annual Data
PDL BioPharma Inc Quarterly Data